Online citations, reference lists, and bibliographies.
← Back to Search

N-Propargyl-1 (R)-aminoindan, Rasagiline, Increases Glial Cell Line-derived Neurotrophic Factor (GDNF) In Neuroblastoma SH-SY5Y Cells Through Activation Of NF-κB Transcription Factor

W. Maruyama, A. Nitta, M. Shamoto-Nagai, Y. Hirata, Y. Akao, Moussa Yodim, S. Furukawa, T. Nabeshima, M. Naoi
Published 2004 · Medicine, Chemistry

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
N-Propargyl-l(R)-aminoindan, rasagiline, an anti-Parkinson drug, was found to increase the protein and mRNA levels of glial cell line-derived neurotrophic factor (GDNF) in human neuroblastoma SH-SY5Y cells, whereas an analogue without a propargyl residue, aminoindan, did not. GDNF is known to protect dopaminergic neurons in animal and cellular models of Parkinson's disease, and the supplement has been tried for the treatment of degenerating dopamine neurons in Parkinsonian patients. In this paper, intracellular mechanism underlying the induction of GDNF was studied. Rasagiline induced phosphorylation of inhibitory subunit (IkappaB) of nuclear factor-kappaB (NF-kappaB), and translocation of active p65 subunit from cytoplasm into nuclei. Activation of NF-kappaB was also quantitatively determined by NF-kappaB p65 transcription assay. Sulfasalazine, an inhibitor of IkappaB kinase, suppressed the activation of NF-kappaB and the increase of GDNF by rasagiline simultaneously, further indicating the involvement of the IkappaB kinase-NF-kappaB pathway. The results on the activation of the transcription factor by rasagiline are discussed in relation to its possible application as a neuroprotective drug to halt declining of neurons in neurodegenerative disorders, such as Parkinson's and Alzheimer's diseases.
This paper references
10.1212/WNL.14.1.69
Encephalomyelopathy due to an organic mercury compound
S. Okinaka (1964)
10.1016/0003-2697(76)90527-3
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
M. M. Bradford (1976)
10.1126/science.7878464
Apoptosis in the pathogenesis and treatment of disease
C. Thompson (1995)
10.1038/373335A0
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
A. Tomac (1995)
10.1007/978-3-7091-7494-4_9
Pharmacology and neuroprotective properties of rasagiline.
J. Finberg (1996)
10.1046/j.1471-4159.1996.66020869.x
Ceramide Protects Hippocampal Neurons Against Excitotoxic and Oxidative Insults, and Amyloid β‐Peptide Toxicity
Y. Goodman (1996)
10.1073/PNAS.94.6.2642
Transcription factor NF-κB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimer disease
B. Kaltschmidt (1997)
10.1073/PNAS.94.14.7531
Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease.
S. Hunot (1997)
10.1172/JCI992
Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.
C. Wahl (1998)
10.1124/MOL.53.1.33
Nuclear Factor-κB Contributes to Excitotoxin-Induced Apoptosis in Rat Striatum
Z. Qin (1998)
10.1016/S0306-4522(98)00469-2
Endogenous neurotrophin-3 is retrogradely transported in the rat sciatic nerve
A. Nitta (1999)
10.1073/PNAS.96.16.9409
Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis.
B. Kaltschmidt (1999)
10.1016/S0006-2952(98)00214-7
Nuclear factor-κB/Rel proteins: A point of convergence of signalling pathways relevant in neuronal function and dysfunction
M. Grilli (1999)
10.1016/S0047-6374(99)00066-4
Neuroprotection by (−)-deprenyl and related compounds
W. Maruyama (1999)
10.1074/jbc.274.13.8531
Tumor Necrosis Factor Induces Bcl-2 and Bcl-x Expression through NFκB Activation in Primary Hippocampal Neurons*
Michio Tamatani (1999)
10.1146/ANNUREV.IMMUNOL.18.1.621
Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.
M. Karin (2000)
10.1007/978-3-7091-6301-6_11
Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022.
W. Maruyama (2000)
10.1016/S0024-3205(00)00643-3
Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat.
M. Carrillo (2000)
10.1006/exnr.2000.7489
Increased Caspase 3 and Bax Immunoreactivity Accompany Nuclear GAPDH Translocation and Neuronal Apoptosis in Parkinson's Disease
N. Tatton (2000)
10.1046/j.1471-4159.2000.740443.x
Roles of Nuclear Factor κB in Neuronal Survival and Plasticity
M. Mattson (2000)
10.1053/GAST.2000.19458
Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β
C. Weber (2000)
10.1074/jbc.m010821200
NFκB-dependent Transcriptional Activation during Heat Shock Recovery
C. Kretz-remy (2001)
10.1523/JNEUROSCI.21-13-04668.2001
Activation of the Nuclear Factor-κB Is a Key Event in Brain Tolerance
N. Blondeau (2001)
10.1046/j.1471-4159.2001.00448.x
Transfection‐enforced Bcl‐2 overexpression and an anti‐Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde‐3‐phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N‐methyl(R)salsolinol
W. Maruyama (2001)
10.1007/s007020170093
Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine
W. Maruyama (2001)
10.1074/JBC.M010821200
NFkappa B-dependent transcriptional activation during heat shock recovery. Thermolability of the NF-kappaB.Ikappa B complex.
C. Kretz-remy (2001)
10.1046/j.1471-4159.2002.00880.x
NF‐κB‐mediated up‐regulation of Bcl‐XS and Bax contributes to cytochrome c release in cyanide‐induced apoptosis
Yan Shou (2002)
10.1007/978-0-306-47593-1_79
FK506 Protects Dopaminergic Degeneration Through Induction of GDNF in Rodent Brains
A. Nitta (2002)
10.1124/JPET.301.2.753
Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells.
W. Tatton (2002)
10.1096/fj.02-0198fje
The involvement of mitogen‐activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline
M. Yogev-Falach (2002)
10.1046/j.1471-4159.2002.01232.x
Oxidative modulation of nuclear factor‐κB in human cells expressing mutant fALS‐typical superoxide dismutases
A. Casciati (2002)
10.1523/JNEUROSCI.22-12-04942.2002
Lentivirally Delivered Glial Cell Line-Derived Neurotrophic Factor Increases the Number of Striatal Dopaminergic Neurons in Primate Models of Nigrostriatal Degeneration
S. Palfi (2002)
10.1001/ARCHNEUR.59.12.1937
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
A. Siderowf (2002)
10.1038/sj.gt.3301682
Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease
L. Wang (2002)
10.1007/978-0-306-47593-1
Mapping the Progress of Alzheimer’s and Parkinson’s Disease
水野 美邦 (2002)
10.1016/S0304-3940(02)00332-4
An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells
Y. Akao (2002)
10.1046/j.1471-4159.2002.01047.x
Mitochondrial permeability transition mediates apoptosis induced by N‐methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl‐2 and rasagiline, N‐propargyl‐1(R)‐aminoindan
Y. Akao (2002)
10.1007/s007020200038
The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells
W. Maruyama (2002)
10.1212/WNL.60.1.69
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
J. Nutt (2003)
10.1038/nm850
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
S. Gill (2003)



This paper is referenced by
10.1007/s00702-020-02150-w
Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson’s disease
M. Naoi (2020)
10.5607/en19075
Induction of GDNF and GFRα-1 Following AAV1-Rheb(S16H) Administration in the Hippocampus in vivo
Dongyoung Yun (2020)
10.1111/jphp.13244
TV 3326 for Alzheimer’s dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer’s‐like neuropathology
Sahab Uddin (2020)
Interneuronas estriatales productoras de GDNF: características moleculares y rol en la neuroprotección catecolaminérgica
Daniel Enterría Morales (2019)
10.1002/cbic.201800813
Structure‐Based Specific Detection and Inhibition of Monoamine Oxidases and Their Applications in Central Nervous System Diseases
Riri Shi (2019)
10.1111/cns.12805
Rasagiline delays retinal degeneration in a mouse model of retinitis pigmentosa via modulation of Bax/Bcl‐2 expression
A. B. Garcia-Delgado (2018)
10.1007/s00702-018-1853-9
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease
É. Szökő (2018)
10.1007/s00702-017-1832-6
Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons
M. Naoi (2017)
10.1007/s00702-017-1740-9
Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline
Keiko Inaba-Hasegawa (2017)
10.1007/s00702-017-1797-5
Neurotrophic function of phytochemicals for neuroprotection in aging and neurodegenerative disorders: modulation of intracellular signaling and gene expression
M. Naoi (2017)
Investigating chondroitin sulphate proteoglycans as a therapeutic target for Parkinson's disease
E. J. Fletcher (2017)
10.1515/revneuro-2016-0063
Role of glial cell line-derived neurotrophic factor in the pathogenesis and treatment of mood disorders
A. Tsybko (2017)
10.1016/j.brainres.2015.11.028
BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson׳s disease
A. Ledreux (2016)
10.1016/B978-0-444-63932-5.00005-X
Bioactive Dietary Compounds Regulate Mitochondrial Apoptosis Signaling in Ambivalent Way to Function as Neuroprotective or Antitumor Agents
M. Naoi (2016)
Influence of different neuroprotective drugs on dopamine neurotoxicity induced by 3,4-methylenedioxymethamphetamine and MPTP in mice
Pier Francesca Porceddu (2016)
10.1016/j.drudis.2016.08.001
Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders.
P. Bawa (2016)
10.1186/s40478-016-0279-6
Animal modeling an oligodendrogliopathy – multiple system atrophy
Jonathan M. Bleasel (2016)
10.3389/fnana.2015.00010
GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson’s disease
X. d’Anglemont de Tassigny (2015)
10.1016/j.nbd.2015.07.012
Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease
G. Cisbani (2015)
10.1016/j.neurobiolaging.2015.05.009
Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice
O. Weinreb (2015)
10.1007/978-3-319-05392-9_32
Anti-Parkinson Activity
M. Kallman (2015)
Cystamine / cysteamine rescue the dopaminergic system and show neurorestorative properties in an animal model of Parkinson ’ s disease
J. Drouin-Ouellet (2015)
10.1007/s10571-015-0241-3
Gas1 Knockdown Increases the Neuroprotective Effect of Glial Cell-Derived Neurotrophic Factor Against Glutamate-Induced Cell Injury in Human SH-SY5Y Neuroblastoma Cells
K. Wang (2015)
10.1111/cns.12312
Lenti‐GDNF Gene Therapy Protects Against Alzheimer's Disease‐Like Neuropathology in 3xTg‐AD Mice and MC65 Cells
Susana Revilla (2014)
Identification of novel scaffolds for Monoamine oxidase B inhibitors
H. Odhar (2014)
10.1007/978-94-007-7920-4_11
Role of lipid peroxide in the neurodegenerative disorders.
W. Maruyama (2014)
10.1007/978-94-007-7920-4
Lipid Hydroperoxide-Derived Modification of Biomolecules
Y. Kato (2014)
10.1007/s00702-014-1362-4
Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression
M. Naoi (2014)
10.3892/ijmm.2013.1450
Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.
Q. Zhao (2013)
10.1007/s00702-013-1033-x
Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria
M. Naoi (2013)
10.1586/ern.13.60
Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms
M. Naoi (2013)
10.7916/D8794BX2
Part I: Catalytic Direct C-H Arylation of Pyrazoles Part II: Toward Modulation of Neuroplasticity with Small Molecules
T. Jacques (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar